Despite Rheumatologist Reports that BMS’ Orencia is Their Preferred Non-TNF Agent for Treating Rheumatoid Arthritis, Pfizer’s Xeljanz Provides Steep Competition in Actual Switching Patterns
Patient Requests are a Key Driver Behind Switching Brands in Rheumatoid Arthritis, according to a Recently Released Study by Spherix Global Insights Download Report Overview EXTON, Pa., Oct. 16, 2017 /PRNewswire/ — Spherix Global Insights announces the release of the 2017 edition of RealWorld Dynamix™: Biologic and JAK Switching in RA, a project undertaken in […]
Analysis of Over 1000 Psoriatic Arthritis (PsA) Patients Reveals Large Candidate Pool for Pfizer’s Xeljanz, BMS’ Orencia, and Eli Lilly’s Taltz
According to Spherix Global Insights, the analysis indicates an increase in biologic switching rates compared to the prior year with a growing movement away from TNF cycling, opening doors for earlier use of alternative mechanism agents Download Report Overview EXTON, Pa., Sept. 26, 2017 /PRNewswire/ — According to a new sub-analysis of PsA patients recently […]
Cosentyx Plateaus as Non-TNF Agents Prepare to Dominate in Psoriatic Arthritis
From: Specialty Pharma Time By: Lauren Santye Although there are a growing number of rheumatologists in the United States who report the use of Cosentyx to treat psoriatic arthritis (PsA), the increasing user base has failed to translate into overall increases in biologic share, according to market research company Spherix Global Insights. The plateau of […]
Novartis’ Cosentyx Beginning to Plateau in Psoriatic Arthritis, as US Rheumatologists Prepare for an Influx of Non-TNF Agents, Such as BMS’ Orencia, Pfizer’s Xeljanz, and Lilly’s IL-17, Taltz
Despite an increasing user base, Cosentyx share has remained unchanged over the past six months, according to recently released data from Spherix Global Insights Download Report Overview EXTON, Pa., Aug. 15, 2017 /PRNewswire/ — In the most recent quarterly update of RealTime Dynamix™ Psoriatic Arthritis, a growing population of US rheumatologists (n=101) are reporting use […]
RealWorld Dynamix™: Biologic/JAK Switching in RA US 2017
There are currently nine biologics, one biosimilar, and one oral janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis (RA) in the United States. With the more established TNF-inhibiting biologics on the market for nearly two decades, RA treatment protocol and payer policy tend to dictate their use as first-line biologics. However, rheumatologists […]
Likely Delay for Janssen’s Sirukumab Sets up Head to Head Battle Between Roche/Genentech’s Actemra and Sanofi/Regeneron’s Kevzara in the US Rheumatoid Arthritis Market
Despite Kevzara’s aggressive pricing play, early launch metrics of the newest IL-6 inhibitor, indicate conservative uptake, according to Spherix Global Insight’s most recent quarterly update Download Report Overview EXTON, Pa., Aug. 9, 2017 /PRNewswire/ — Following an unfavorable recommendation from the FDA’s Arthritis Advisory Committee, it is unlikely that sirukumab will gain approval anytime in […]
Can Pharma Companies Expand the Current Ankylosing Spondylitis (AS) Market with a New Indication for Non-Radiographic Axial Spondyloarthropathy (nr-axSpA)? Novartis and UCB Pharma Are Just Two Companies Angling to Bring Approved Treatments to These Patients in the Near Future
According a new report from Spherix Global Insights, biologic treatment of nr-axSpA is complicated by multiple factors resulting in a significantly lower percentage of patients with nr-axSpA being treated compared to those with AS Download Report Overview EXTON, Pa., Aug. 1, 2017 /PRNewswire/ — An independent study conducted by Spherix Global Insights in June with […]
RealTime Dynamix™: Ankylosing Spondylitis & Non-radiographic Axial Spondyloarthritis US Q2
Use of biologics in the management of axial spondyloarthropathies (axSpA) has become well established in psoriatic arthritis and ankylosing spondylitis (AS). The spectrum of axSpA is becoming better understood and now includes inflammation in the absence of observable damage using radiographic techniques (nr-axSpA). In nr-axSpA, the impact on quality of life is rated as high, […]
BMS’ Orencia Plunges into the Fray of Battle for Alternative MOA for Psoriatic Arthritis with Recent FDA Approval…. Can it Find a Unique Space to Play?
Approval of Orencia for Psoriatic Arthritis (PsA) opens door for expansion of use based on existing off-label experience, adding further challenge to Novartis’s Cosentyx and Janssen’s Stelara for preferred TNF alternative, according to recent reports from Spherix Global Insights. Download Report Overview EXTON, Pa., July 6, 2017 /PRNewswire/ — BMS’ Orencia, already indicated for Rheumatoid […]
Novartis’ Cosentyx Takes the Wind Out of Stelara’s Sails in Psoriatic Arthritis Market
New findings in a recent study by Spherix Global Insights, RealWorld Dynamix™: Biologic and Otezla Switching in PsA, indicate an increased rate of switching to the brand and strong momentum for Cosentyx compared to previous results collected in November 2015 Download Report Overview EXTON, Pa., May 16, 2017 /PRNewswire/ — A recent patient chart analysis […]
